FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017169843> ?p ?o ?g. }

• W2017169843 endingPage "853" @default.
• W2017169843 startingPage "847" @default.
• W2017169843 abstract "In Brief Objective: The National Quality Forum has endorsed a quality metric concerning the use of adjuvant chemotherapy administration in stage III colon cancer, yet a substantial treatment gap exists. Our objective was to evaluate the association of postoperative complications on the use of adjuvant therapy after colectomy for cancer. Patients and Methods: Data from the American College of Surgeons National Surgical Quality Improvement Program and National Cancer Data Base were linked to augment cancer registry information with robust clinical data on comorbidities and postoperative complications (2006–2008). The association of complications on adjuvant chemotherapy use was assessed using hierarchical multivariable regression models. Results: From 126 hospitals, 2368 patients underwent resection for stage III colon adenocarcinoma. Overall utilization of adjuvant chemotherapy was 63.2% (1497/2368). Of the 871 patients who did not receive chemotherapy, 652 met National Quality Forum exclusion criteria: death, severe comorbidity, refusal of care, advanced age (≥80 years), or prior malignancy. Of the remaining 219 patients, 19.1% (42/219) had 1 or more serious postoperative complications (eg, pneumonia, pulmonary failure). After accounting for the aforementioned potential explanations, the utilization rate was 87.2% (1497/1716). The strongest predictors of adjuvant chemotherapy omission were prolonged postoperative ventilation, renal failure, reintubation, and pneumonia (all Ps < 0.05). Superficial surgical site infection did not decrease adjuvant therapy receipt but delayed the time to its use by 3-fold. Serious complications increased time to chemotherapy by 65%. Abscess/anastomotic leak increased time to adjuvant chemotherapy by more than 5-fold. Conclusions: Serious postoperative complications explained nearly 20% of the adjuvant chemotherapy treatment gap for patients with stage III colon cancer. The use of clinical data remains important when judging provider performance. Adjuvant chemotherapy in stage III colon cancer prolongs survival and is a National Quality Forum–endorsed quality metric that will be used to publicly evaluate hospitals. Evidence indicates that a large proportion of eligible patients never receive treatment, but no study has comprehensively investigated the contribution of postoperative complications. We found that complications were strongly associated with adjuvant therapy omission or treatment delays and explained nearly 20% of the adjuvant chemotherapy treatment gap for patients with stage III colon cancer." @default.
• W2017169843 created "2016-06-24" @default.
• W2017169843 creator A5011684815 @default.
• W2017169843 creator A5016722648 @default.
• W2017169843 creator A5023012457 @default.
• W2017169843 creator A5032770196 @default.
• W2017169843 creator A5036972230 @default.
• W2017169843 creator A5037610787 @default.
• W2017169843 creator A5075432941 @default.
• W2017169843 creator A5082462970 @default.
• W2017169843 creator A5083322488 @default.
• W2017169843 creator A5086411600 @default.
• W2017169843 date "2013-12-01" @default.
• W2017169843 modified "2023-10-06" @default.
• W2017169843 title "Effect of Postoperative Complications on Adjuvant Chemotherapy Use for Stage III Colon Cancer" @default.
• W2017169843 cites W2004079062 @default.
• W2017169843 cites W2007743877 @default.
• W2017169843 cites W2019718580 @default.
• W2017169843 cites W2027221490 @default.
• W2017169843 cites W2065598801 @default.
• W2017169843 cites W2094002362 @default.
• W2017169843 cites W2104561577 @default.
• W2017169843 cites W2118961573 @default.
• W2017169843 cites W2122136304 @default.
• W2017169843 cites W2129309727 @default.
• W2017169843 cites W2137419492 @default.
• W2017169843 cites W2139003935 @default.
• W2017169843 cites W2141218183 @default.
• W2017169843 cites W2145131986 @default.
• W2017169843 cites W2165948908 @default.
• W2017169843 cites W2167546181 @default.
• W2017169843 cites W2169449551 @default.
• W2017169843 cites W2255487108 @default.
• W2017169843 cites W2313857605 @default.
• W2017169843 cites W2598363796 @default.
• W2017169843 cites W4233272864 @default.
• W2017169843 doi "https://doi.org/10.1097/sla.0000000000000312" @default.
• W2017169843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24169157" @default.
• W2017169843 hasPublicationYear "2013" @default.
• W2017169843 type Work @default.
• W2017169843 sameAs 2017169843 @default.
• W2017169843 citedByCount "101" @default.
• W2017169843 countsByYear W20171698432013 @default.
• W2017169843 countsByYear W20171698432014 @default.
• W2017169843 countsByYear W20171698432015 @default.
• W2017169843 countsByYear W20171698432016 @default.
• W2017169843 countsByYear W20171698432017 @default.
• W2017169843 countsByYear W20171698432018 @default.
• W2017169843 countsByYear W20171698432019 @default.
• W2017169843 countsByYear W20171698432020 @default.
• W2017169843 countsByYear W20171698432021 @default.
• W2017169843 countsByYear W20171698432022 @default.
• W2017169843 countsByYear W20171698432023 @default.
• W2017169843 crossrefType "journal-article" @default.
• W2017169843 hasAuthorship W2017169843A5011684815 @default.
• W2017169843 hasAuthorship W2017169843A5016722648 @default.
• W2017169843 hasAuthorship W2017169843A5023012457 @default.
• W2017169843 hasAuthorship W2017169843A5032770196 @default.
• W2017169843 hasAuthorship W2017169843A5036972230 @default.
• W2017169843 hasAuthorship W2017169843A5037610787 @default.
• W2017169843 hasAuthorship W2017169843A5075432941 @default.
• W2017169843 hasAuthorship W2017169843A5082462970 @default.
• W2017169843 hasAuthorship W2017169843A5083322488 @default.
• W2017169843 hasAuthorship W2017169843A5086411600 @default.
• W2017169843 hasConcept C121608353 @default.
• W2017169843 hasConcept C126322002 @default.
• W2017169843 hasConcept C141071460 @default.
• W2017169843 hasConcept C146357865 @default.
• W2017169843 hasConcept C151730666 @default.
• W2017169843 hasConcept C2776694085 @default.
• W2017169843 hasConcept C2777982462 @default.
• W2017169843 hasConcept C526805850 @default.
• W2017169843 hasConcept C71924100 @default.
• W2017169843 hasConcept C86803240 @default.
• W2017169843 hasConceptScore W2017169843C121608353 @default.
• W2017169843 hasConceptScore W2017169843C126322002 @default.
• W2017169843 hasConceptScore W2017169843C141071460 @default.
• W2017169843 hasConceptScore W2017169843C146357865 @default.
• W2017169843 hasConceptScore W2017169843C151730666 @default.
• W2017169843 hasConceptScore W2017169843C2776694085 @default.
• W2017169843 hasConceptScore W2017169843C2777982462 @default.
• W2017169843 hasConceptScore W2017169843C526805850 @default.
• W2017169843 hasConceptScore W2017169843C71924100 @default.
• W2017169843 hasConceptScore W2017169843C86803240 @default.
• W2017169843 hasIssue "6" @default.
• W2017169843 hasLocation W20171698431 @default.
• W2017169843 hasLocation W20171698432 @default.
• W2017169843 hasOpenAccess W2017169843 @default.
• W2017169843 hasPrimaryLocation W20171698431 @default.
• W2017169843 hasRelatedWork W134396366 @default.
• W2017169843 hasRelatedWork W167319750 @default.
• W2017169843 hasRelatedWork W2047967234 @default.
• W2017169843 hasRelatedWork W2099859852 @default.
• W2017169843 hasRelatedWork W2275390773 @default.
• W2017169843 hasRelatedWork W2326489905 @default.
• W2017169843 hasRelatedWork W2401392746 @default.
• W2017169843 hasRelatedWork W2435423225 @default.
• W2017169843 hasRelatedWork W2439875401 @default.

• next